Γενόσημα
Gene Therapy / Cell Therapy / Stem Cells – Regulations for the "New Biologics"
FDAAA Title VIII ( PL 110-85, Section 801) Expanded Clinical Trials Registry and Results Database Status Report on Implementation Theresa Toigo Director,
U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES NATIONAL INSTITUTES OF HEALTH Working with FDA: Biological Products and Clinical Development Chemistry, Manufacturing.
Fda update on cord blood reg aabb 2009
Computer system validation
Fiscal Year 2014 Supplemental Funding to Increase HIV Prevention and Care among Health Centers Partnering with State Health Departments (Partnerships for.
1 Resolving SBIR/STTR Allegations of Waste, Fraud, and Abuse - NIH Perspective Presented by: Maritza Zeiberg, CPA, Director, Division of Program Integrity,
Department of Health and Environmental Control 2010-2011 Exercises/Future Exercise Requirements.
Information Call for Funding Opportunity Announcement CDC-RFA-PS15-1501 Tuberculosis Elimination and Laboratory Cooperative Agreement July 10, 2014 Glen.
CBER Introduction to Regulation Robert A. Yetter Associate Director for Review Management Center for Biologics Evaluation and Research.
Fecal Microbiota for Transplantation Jay E. Slater, MD FDA/CBER/OVRR/DBPAP.